Judicial Watch announced on Tuesday that it has received 165 pages of records from the Food and Drug Administration (FDA) through a Freedom of Information request and lawsuit showing contracts between the FDA and Advanced Bioscience Resources (ABR) for the purchase of tissue from aborted babies. The watchdog group said the eight contracts, which were dated from 2012 to 2018, requested “fresh and never frozen” tissue from first and second-trimester aborted babies.
WARNING: Image below may be disturbing for readers.
“These documents are a horror show,” said Judicial Watch President Tom Fitton. “These records show that the FDA was trafficking in human fetal parts. Incredibly, there continues to be a push to reopen these monstrous experiments!”
ABR is a fetal tissue procurement company that has been referred to the FBI for criminal charges regarding the illegal, for-profit trafficking of fetal body parts. The request for “fresh” bodies means that procurement technicians would have been on-site at the abortion businesses to obtain children immediately after they were killed in abortions.
The newly obtained records show an email exchange from June 2017 regarding the “purchase of tissues suitable for HM [humanized mice] research” with a request for a price quote for 16 human fetal livers and 16 human fetal thymuses along with 16 HIV, hepatitis A, hepatitis B, and hepatitis C tests. The Statement of Work included in the email states:
The Division of Applied Regulatory Science (DARS) OCP/OTS/CDER is conducting a research program to evaluate the usefulness of humanized mice (HM) for regulatory purposes. The HM are created by surgical implantation of human tissue into mice that have multiple genetic mutations that block the development of the mouse immune system at a very early stage.
The absence of the mouse immune system allows the human tissues to grow and develop into functional human tissues. As part of this process DARS needs to repeatedly acquire the proper type of tissues. In order for the humanization to proceed correctly we need to obtain fetal tissue with a specific set of specialized characteristics.
The “specialized characteristics” include that the tissue is fresh and that it be from the bodies of babies aborted between 16 and 24 weeks gestation. The email response from ABR states: “Your quote is attached.”
About a month later, in July 2017, an email from an FDA contracting specialist told ABR that “In order to properly document pricing, I require some documentation of your prices as offered to the public.” ABR responded that it does not have prices but attached a Fees for Services Schedule that lists “Fetal Cadaverous Specimen Procurement” with pricing for second-trimester aborted baby parts (13-24 weeks) and first-trimester body parts (8-12 weeks). The document includes “special processing/preservation” feeds for “specimen ‘cleaning,'” “snap freezing,” “passive freezing (dry ice),” and “foreign shipments.”
In July 2018, the FDA ordered the purchase of “humanized mice” from ABR beginning July 26, 2018, through July 25, 2019. That contract required securing 15 sets of second-trimester human fetal livers and thymuses.
In September 2018, the FDA ended the contract with ABR because “[T]he Government has concerns with the sufficiency of the sole-source justification.” That same month, the Department of Health and Human Services issued a statement that it was “conducting an audit of all acquisitions involving human fetal tissue to ensure conformity with procurement and human fetal tissue research laws and regulations.”
In addition to these documents, Judicial Watch was able to secure 676 pages of records from NIH detailing that this government agency had also paid for organs from aborted humans.
“Like” Live Action News on Facebook for more pro-life news and commentary!